Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Nastorazepide is a selective, orally available antagonist of gastrin/cholecystokinin 2 (CCK-2) receptor with potential antineoplastic activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 48.00 | |
5 mg | In stock | $ 97.00 | |
10 mg | In stock | $ 189.00 | |
25 mg | In stock | $ 363.00 | |
50 mg | In stock | $ 553.00 | |
100 mg | In stock | $ 798.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 123.00 |
Description | Nastorazepide is a selective, orally available antagonist of gastrin/cholecystokinin 2 (CCK-2) receptor with potential antineoplastic activity. |
In vitro | Nastorazepide binds to the gastrin/CCK-2 receptor, thereby preventing receptor activation by gastrin, a peptide hormone frequently associated with the proliferation of gastrointestinal and pancreatic tumor cells[1]. |
In vivo | Nastorazepide significantly inhibits the growth of subcutaneous xenografts of human pancreatic tumor cells in mice, and that Nastorazepide combined with gemcitabine prolonged survival in a pancreatic carcinoma orthotopic xenograft mice[1]. |
Synonyms | Z-360 |
Molecular Weight | 520.62 |
Formula | C29H36N4O5 |
CAS No. | 209219-38-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (57.63 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Nastorazepide 209219-38-5 GPCR/G Protein cholecystokinin CCK Receptor Cholecystokinin Receptor Inhibitor Z-360 Z360 inhibit Z 360 inhibitor